Filing Flows › Bio-Techne (TECH) › Guidance & outlook
Bio-Techne (TECH) guidance and outlook
Bio-Techne's 10-Q filed Nov 6, 2026 makes 6 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 6, 2026
- We intend to build on Bio-Techne’s past accomplishments, high product quality reputation and sound financial position by executing strategies that position us to serve as the standard for biological content in the research market, and to leverage that leadership position to enter the diagnostics and other adjacent markets.
- Excluding the impact of discrete items, the Company expects the consolidated income tax rate for the remainder of fiscal 2027 to range from 23% to 27%.
- During fiscal year 2023, Wilson Wolf met the EBITDA target and the Company paid an additional $232 million to acquire 19.9% of Wilson Wolf.
- Management of the Company expects to be able to meet its cash and working capital requirements for operations, facility expansion, capital additions, and cash dividends for the foreseeable future, and at least the next 12 months, through currently available cash, cash generated from operations, and remaining credit available on its existing revolving line of credit.
- Expected additions in fiscal 2027 are related to increasing capacity to meet expected sales growth across the Company.
- The application of certain of these policies requires judgments and estimates that can affect the results of operations and financial position of the Company.
Bio-Techne's latest quarter
Bio-Techne, Q1 FY27: revenue $300M (+5% year over year), operating margin 12.2%, net earnings $28.3M, operating cash flow $73.1M. The chart follows the revenue to costs, profit and cash.
Questions
What does Bio-Techne expect?
We intend to build on Bio-Techne’s past accomplishments, high product quality reputation and sound financial position by executing strategies that position us to serve as the standard for biological content in the research market, and to leverage that leadership position to enter the diagnostics and other adjacent markets. Excluding the impact of discrete items, the Company expects the consolidated income tax rate for the remainder of fiscal 2027 to range from 23% to 27%. During fiscal year 2023, Wilson Wolf met the EBITDA target and the Company paid an additional $232 million to acquire 19.9%
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.